BioXcel Therapeutics, Inc. (BTAI)
NASDAQ: BTAI · Real-Time Price · USD
1.480
-0.050 (-3.27%)
At close: May 12, 2025, 4:00 PM
1.470
-0.010 (-0.68%)
After-hours: May 12, 2025, 7:44 PM EDT
BioXcel Therapeutics Revenue
BioXcel Therapeutics had revenue of $168.00K in the quarter ending March 31, 2025, a decrease of -71.13%. This brings the company's revenue in the last twelve months to $1.85M, up 5.47% year-over-year. In the year 2024, BioXcel Therapeutics had annual revenue of $2.27M with 64.20% growth.
Revenue (ttm)
$1.85M
Revenue Growth
+5.47%
P/S Ratio
2.61
Revenue / Employee
$50,054
Employees
37
Market Cap
8.09M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BTAI News
- 17 hours ago - BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 6 weeks ago - BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces $14 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia - GlobeNewsWire
- 2 months ago - BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewsWire